Novartis is on the final straight to approval of its spinal muscular atrophy (SMA) gene therapy Zolgensma in the EU, after getting a recommendation for approval from the CHMP. The positive opinion ...

Prenatal therapy for spinal muscular atrophy (SMA) with risdiplam has shown promise in a first-of-its-kind study led by Richard Finkel. Roche's Evrysdi has already shown profound benefits in children ...

Unified managed accounts (UMAs) and separately managed accounts (SMAs) are two account types that offer high-net-worth clients more control and flexibility than mutual funds. Both options let you ...

Two children with a rare genetic condition will live very different lives because one was tested at birth and the other was not, their parents say. Marley, five, and Meadow, four months, both have ...

Novartis has received an FDA approval for Itvisma, a new version of the company’s gene therapy Zolgensma, to treat older patients with spinal muscular atrophy (SMA). The approval comes more than six ...

The consensus analyst price target for SMA Solar Technology has recently increased from €17.60 to €18.80, signaling a modest shift in sentiment among industry experts. This revision follows growing ...

SonicWall has released a firmware update that can help customers remove rootkit malware deployed in attacks targeting SMA 100 series devices. "SonicWall SMA 100 10.2.2.2-92sv build has been released ...

SMA management expects negative one-time losses between €170-220 million. Image: SMA Solar. SMA Solar has forecast financial losses and further restructuring measures in 2025, as it responds to ...

Risdiplam, an oral pre–messenger RNA splicing modifier, is an efficacious treatment for persons with symptomatic spinal muscular atrophy (SMA). The safety and efficacy of risdiplam in presymptomatic ...

Scholar Rock’s investigational spinal muscular atrophy drug helped patients taking Eli Lilly’s obesity blockbuster Zepbound maintain muscle mass, offering another avenue to reach a key goal for the ...

Panelists discuss how the current spinal muscular atrophy (SMA) treatment landscape includes 3 options: gene therapy (onasemnogene abeparvovec [Zolgensma]) for younger patients and 2 splice modifiers ...

The first US project featuring the product is expected in the first quarter of 2026. Image: SMA Solar German solar inverter manufacturer SMA Solar will begin local assembly of power systems for ...